ASC 730
Active
Research and Development
Governs research and development costs, requiring all R&D to be expensed as incurred, with specific guidance on software development costs.
1
Conceptual Framework Linkage
Expensing the pursuit of future economic benefits
ASC 730 takes a conservative approach to research and development costs: because the future economic benefits of R&D are inherently uncertain at the time the costs are incurred, the Topic REQUIRES all R&D costs to be EXPENSED as incurred. This reflects the Conceptual Framework's prudence constraint and the difficulty of reliably measuring future benefits from research activities.
2
Scope & Applicability
All research and development activities
ASC 730 applies to ALL research and development activities, including laboratory research, design and testing of new products, modification of existing products, and construction of prototypes. It covers both independently contracted R&D and R&D performed on behalf of others. Software development costs for external sale are treated under ASC 985-20, while costs for internal-use software follow ASC 350-40.
3
The General Rule – All R&D Expensed as Incurred
No capitalisation permitted for general R&D
ALL research and development costs must be EXPENSED as incurred under ASC 730. This includes materials, equipment, personnel costs, and indirect costs directly related to R&D activities. Contract research is similarly expensed. The only exception is software development costs after technological feasibility is established, which follow ASC 350-40 guidance.
4
Software Development Costs (350-40) – the Capitalisation Exception
A narrow capitalisation carve-out
Software development costs may be CAPITALISED once TECHNOLOGICAL FEASIBILITY is established – that is, the entity has completed all planning, designing, coding, and testing activities necessary to establish that the product can be produced to meet its design specifications. Before technological feasibility, costs are expensed as R&D. After feasibility, costs are capitalised and amortised over the software's expected useful life.
5
Research vs Development – the Conceptual Distinction
Both are expensed, but the distinction matters
RESEARCH is planned investigation or search undertaken to discover new knowledge or to apply that knowledge to a new product or process – broad, exploratory, without a specific commercial objective. DEVELOPMENT is the translation of research findings into a plan or design for a new product or process – more focused, with a specific commercial application in mind. Both stages are EXPENSED as incurred under ASC 730, but the distinction matters for disclosure purposes and for the software capitalisation exception.
6
Capitalisation Trigger – Technological Feasibility
A high threshold for software capitalisation
Technological feasibility requires evidence that the software product can be produced to meet its design specifications, including completion of a product design document, completion of a working model based on the design document, or completion of all critical coding and testing activities. This is a HIGH threshold – early-stage development work, including high-risk coding and initial design iterations, is expensed before the threshold is met.
7
Amortisation of Capitalised Software
Greater of straight-line or revenue-based approach
Capitalised software development costs are amortised using the greater of: (1) the STRAIGHT-LINE method over the estimated useful life of the software, or (2) the REVENUE-BASED method, which amortises proportionally to the ratio of current period revenue to total anticipated revenue. The useful life generally does not exceed 3 to 5 years for most software products.
8
Worked Example – R&D Expense Recognition
Expensing R&D costs during the year
Example: Laboratory research costs
A pharmaceutical company incurs $2,400,000 in R&D costs during the year: $1,200,000 in personnel costs for research scientists, $800,000 in laboratory materials and supplies, $300,000 in clinical trial costs, and $100,000 in R&D facility depreciation.
ALL costs are EXPENSED as incurred under ASC 730: Personnel ($1,200,000) + Materials ($800,000) + Clinical trials ($300,000) + Facility depreciation ($100,000) = $2,400,000 R&D expense recognised in the income statement. None are capitalised as an asset.
9
Disclosure Requirements
What ASC 730 requires
Total R&D expense for the periodSignificant R&D activities, including amounts for major projects or categoriesR&D costs incurred for others, if materialSoftware development costs capitalised and amortised
10
Critical Judgments & Estimates
Where judgement matters most
SIGNIFICANT JUDGEMENTS
When technological feasibility is achieved for software projectsDistinguishing between research and development phasesWhether costs are directly related to R&D activities
SIGNIFICANT ESTIMATES
Useful life for amortisation of capitalised softwareTotal anticipated revenue for revenue-based amortisationAllocation of indirect costs to R&D activities
11
ASC 730 vs IAS 38 – Comprehensive Comparison
Comparison – ASC 730 vs IAS 38
FeatureUS GAAP (ASC 730)IFRS (IAS 38)
Research costsExpensed as incurredExpensed as incurred
Development costsExpensed as incurred (except software)Capitalised when technical feasibility and intent to complete are demonstrated
Software capitalisationAfter technological feasibility (ASC 350-40)IAS 38 criterion for software is similar
The SINGLE BIGGEST divergence: IAS 38 permits capitalisation of DEVELOPMENT costs (other than software) when specific criteria are met, while ASC 730 does NOT permit development cost capitalisation for most industries – a genuinely fundamental difference.
12
Statement Mapping
Where every ASC 730 event lands
EventStatement(s) affectedNotes
R&D expenseISExpensed as incurred
Capitalised software amortisationISAmortised over useful life
13
Related Topics
Cross-reference map
TopicConnection
ASC 350Intangibles – software development costs are capitalised under ASC 350-40
ASC 340Other Assets and Deferred Costs – direct-response advertising capitalisation
IAS 38Intangible Assets – IFRS counterpart permitting development cost capitalisation
Financial statement key
BS Balance sheet
IS Income statement
SE Statement of changes in equity
OCI Other comprehensive income
SCF Statement of cash flows